Sildenafil, the active compound in medications commonly known as Viagra, was initially developed to treat conditions related to impaired blood flow, specifically hypertension and arterial pain stemming from reduced circulation. Over the past three decades, its use has become most widely recognized for managing erectile dysfunction. However, recent scientific investigations suggest the drug may possess novel therapeutic applications beyond its established uses, particularly in oncology.
A study published in Cancer Research detailed findings from the laboratory of Prof. Ajeet Erez, indicating that sildenafil exhibits the ability to limit the metastasis of cancer cells through a previously undocumented biological mechanism. Researchers, including those led by Dr.
Jarden Ariava, demonstrated that the drug interferes with a critical metabolic pathway utilized by malignant cells. Specifically, sildenafil appears to restrict the capacity of cancer cells to utilize cholesterol. Cholesterol is recognized as an essential structural component of all cell membranes.
By disrupting the cells’ access to this vital nutrient, the drug appears to impede the processes necessary for cancer cells to spread and establish secondary sites of growth. This research suggests that the compound’s interaction with cellular biochemistry provides a potential new avenue for anti-cancer therapy. These findings open possibilities for repurposing sildenafil, shifting its focus from vascular health and sexual function toward the management of aggressive malignancies.
Topics: #viagra #cancer #blood
